CERS Stock Overview
Operates as a biomedical products company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cerus Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.57 |
| 52 Week High | US$2.59 |
| 52 Week Low | US$1.38 |
| Beta | 1.24 |
| 1 Month Change | -11.30% |
| 3 Month Change | -7.65% |
| 1 Year Change | -22.66% |
| 3 Year Change | -74.92% |
| 5 Year Change | -65.87% |
| Change since IPO | -87.05% |
Recent News & Updates
Cerus Corporation's (NASDAQ:CERS) Shares Leap 26% Yet They're Still Not Telling The Full Story
Dec 03
Cerus Corporation (NASDAQ:CERS) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 26Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results
Aug 04Cerus Corporation's (NASDAQ:CERS) 30% Jump Shows Its Popularity With Investors
Jul 18Recent updates
Cerus Corporation's (NASDAQ:CERS) Shares Leap 26% Yet They're Still Not Telling The Full Story
Dec 03Cerus Corporation (NASDAQ:CERS) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 26Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results
Aug 04Cerus Corporation's (NASDAQ:CERS) 30% Jump Shows Its Popularity With Investors
Jul 18Does Cerus (NASDAQ:CERS) Have A Healthy Balance Sheet?
Jul 12The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 05Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt
Apr 12Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company
Mar 07Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch
Jan 18Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?
Oct 06Is Cerus (NASDAQ:CERS) A Risky Investment?
Jul 07Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch
May 12Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)
Sep 29Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M
Aug 04Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside
Jul 14Is Cerus (NASDAQ:CERS) Using Debt In A Risky Way?
Jul 06Is Cerus (NASDAQ:CERS) Using Debt Sensibly?
Mar 17Shareholder Returns
| CERS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.4% | -2.1% | -2.8% |
| 1Y | -22.7% | 9.9% | 24.1% |
Return vs Industry: CERS underperformed the US Medical Equipment industry which returned 9.9% over the past year.
Return vs Market: CERS underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| CERS volatility | |
|---|---|
| CERS Average Weekly Movement | 9.9% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CERS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CERS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 631 | Obi Greenman | www.cerus.com |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus Corporation Fundamentals Summary
| CERS fundamental statistics | |
|---|---|
| Market cap | US$286.00m |
| Earnings (TTM) | -US$19.72m |
| Revenue (TTM) | US$176.23m |
1.7x
P/S Ratio-14.8x
P/E RatioIs CERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERS income statement (TTM) | |
|---|---|
| Revenue | US$176.23m |
| Cost of Revenue | US$78.13m |
| Gross Profit | US$98.10m |
| Other Expenses | US$117.82m |
| Earnings | -US$19.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 55.66% |
| Net Profit Margin | -11.19% |
| Debt/Equity Ratio | 153.6% |
How did CERS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 04:50 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cerus Corporation is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | BTIG |